BACKGROUND There are around 350 million of hepatitis B surface antigen (HBsAg) carriers worldwide, and among them, high risk of developing hepatocellular carcinoma (HCC) has been identified by epidemiological studies. To date, the molecular role of HBsAg in HCC development has not been fully studied. We have previously reported that in cell cultures, HBsAg up-regulated the expression of lymphoi...

OBJECTIVE The purpose of this study was to determine the association between PD1 expression and the clinical prognosis of diffuse large B-cell lymphoma (DLBCL) co-occurring with hepatitis B virus (HBV) infection. METHODS A total of 165 patients presented with newly diagnosed and untreated DLBCL at the First Hospital of Jilin University, Changchun, China, between 2011.01 and 2014.12. Complete ...

background chronic hepatitis b consists of different clinical phases. laboratory and histological assessments can help differentiate the clinical phases of this disease and thus lead to better management. objectives this study was conducted to determine laboratory and histological characteristics of hbeag-negative and hbeag-positive chronic hepatitis b patients. patients and methods in this stu...

background: hepatitis b is considered as one of the most common infectious diseases. the contamination of this virus has caused hygienic problems all over the world. liver cirrhosis and hepatocellular carcinoma are most important consequences of this disease. the purpose of this study is to determine the rate of infection in tabriz north west of iran. m aterials and methods: this study is carri...

To determine the clinical implications of HBSAg in severe chronic active liver disease (CALD), patients with HBSAg positive CALD were compared with those chosen by identical clinical, functional, and morphological criteria in whom this test and anti-HBS were negative. HBSAg positive patients were predominantly males over 40 years of age and more frequently failed to respond to conventional trea...

One possibility to increase the organ pool is to use grafts from hepatitis B virus (HBV) surface antigen (HBsAg)-positive donors, but few data are currently available in this setting. Herein, we reviewed the outcome of 92 liver transplantations using allografts from HBsAg-positive donors in the United States (1990-2009). They had experienced HBV-related (n = 68) or HBV-unrelated disease (n = 24...

We tracked the Hepatitis B virus-like vesicles (the surface antigen of Hepatitis B virus, HBsAg) infecting living cells by real-time laser confocal fluorescence imaging. The results show a vesicle-associated movement in the early stage of endocytic trafficking of HBsAg near the plasma membrane. Tracking the internalized HBsAg in the later stage of infection reveals that most HBsAg particles are...

Results: VR at 48 weeks post-treatment, defined as HBeAg seroconversion and HBV DNA less than 10 000 copies/mL was achieved in 10 (33.3%) patients. Responders had significantly lower baseline HBsAg, HBeAg, cccDNA and intrahepatic HBV DNA levels than non-responders. Baseline and reduced levels of log10 HBsAg and log10 HBeAg correlated well with those of log10 cccDNA and log10 total intrahepatic ...

The long surface antigen (L-HBsAg) of hepatitis B virus (HBV) plays a central role in the production of infectious virions. During HBV morphogenesis, both the PreS and S domains of L-HBsAg form docking sites for the viral nucleocapsids. Thus, a compound that disrupts the interaction between the L-HBsAg and nucleocapsids could serve as a therapeutic agent against the virus based upon inhibition ...